• The initiative, funded by the Innovative Health Initiative and supported by the European Union, has a budget of over 50 million euros and brings together 62 academic and industrial partners from 25 countries

• Atrys will draw on its expertise in clinical genomics, pharmacogenomics and personalised medicine to help develop predictive models of cardiovascular risk in cancer patients

• COMPASS aims to transform care in cardio-oncology through artificial intelligence, advanced biomarkers, imaging technologies, digital devices and integrated care models

Atrys Health, a medical company specialising in healthcare services in the fields of oncology, telediagnostics, pathological anatomy and nuclear medicine, has joined the COMPASS project — Cardio Oncology Multidisciplinary Patient Assistance Solution —, the largest European consortium on cancer-related cardiotoxicity, which aims to improve the prevention, early detection and management of cardiovascular complications associated with cancer and its treatments.

The initiative, funded by the Innovative Health Initiative (IHI) with support from the European Union, has a budget of over 50 million euros and brings together 62 partners from 25 countries, including hospitals, research centres, universities, medical technology companies, SMEs and patient organisations. It is coordinated academically by King’s College London and, at an industrial level, by GE HealthCare.

Atrys will contribute its expertise in clinical genomics, pharmacogenomics and personalised medicine to the development of predictive models of cardiovascular risk in cancer patients, with the aim of anticipating the cardiotoxicity associated with treatments and improving clinical decision-making. Furthermore, it will participate in activities related to the integration of clinical data, biomarkers and imaging, as well as in the assessment of the feasibility, sustainability and clinical application of the solutions developed.

Over the next five years, COMPASS will work on designing new tools that will integrate artificial intelligence, advanced biomarkers, imaging technologies and digital devices, with the aim of supporting patients throughout their entire care journey and improving coordination between oncology and cardiology.

“For Atrys, participating in COMPASS means contributing, through clinical genomics and personalised medicine, to one of the major challenges facing oncology today: anticipating and preventing cardiovascular complications associated with cancer treatments. Our aim is to help ensure that advances in research translate into useful tools for healthcare professionals and into more precise and personalised care for patients,” says José Antonio López Martín, head of the Research and Innovation department at Atrys.

Advances in oncology have improved survival rates, but cardiotoxicity remains a growing challenge for healthcare systems due to its complexity, its delayed onset and the need to integrate different areas of care. Against this backdrop, COMPASS will work on new tools to better predict risk, personalise monitoring and support clinical decision-making.

Through its participation in this project, Atrys is reinforcing its commitment to innovation, precision medicine and the development of clinical solutions aimed at improving patients’ quality of life and addressing the major challenges facing modern oncology.

Further information on the project: COMPASS Project – Innovating heart health for cancer care